Invesaro

Stocks Health care HAE

NYSE · Health care

Haemonetics Corp (HAE)

Haemonetics Corp brought in $1.4B of revenue over the twelve months to June 27, 2026, up 0.4% from a year earlier. Net income was $96.3M, a net margin of 7.1%. Operating cash flow minus capital spending left $260.4M of free cash flow in fiscal 2026. At June 27, 2026 it held $223.4M in cash against $1.2B of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Revenue (last 12 months)
$1.4B
+0.4% year on year
Net margin
7.1%

What Haemonetics Corp does

Haemonetics Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker HAE.

Revenue and profit by year

Revenue
FY19: $967.6M $967.6M FY19FY20: $988.5M $988.5M FY20FY21: $870.5M $870.5M FY21FY22: $993.2M $993.2M FY22FY23: $1.2B $1.2B FY23FY24: $1.3B $1.3B FY24FY25: $1.4B $1.4B FY25FY26: $1.3B $1.3B FY26
Net income
FY19: $55M $55M FY19FY20: $76.5M $76.5M FY20FY21: $79.5M $79.5M FY21FY22: $43.4M $43.4M FY22FY23: $115.4M $115.4M FY23FY24: $117.6M $117.6M FY24FY25: $167.7M $167.7M FY25FY26: $97.3M $97.3M FY26

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal yearRevenueOperating incomeNet incomeDiluted EPSFree cash flow
2026$1.3B$156.7M$97.3M$2.05$260.4M
2025$1.4B$221.8M$167.7M$3.31$142.4M
2024$1.3B$164.9M$117.6M$2.29$143.6M
2023$1.2B$156M$115.4M$2.24$81.7M
2022$993.2M$80.8M$43.4M$0.84$75.8M
2021$870.5M$89.7M$79.5M$1.55$71.8M

Latest SEC filings

What Haemonetics Corp has filed recently, newest first. Each links to the original document on SEC EDGAR.

  1. August 18, 2026
    Investor disclosure 8-K
  2. August 12, 2026
    Passive stake changed SCHEDULE 13G/A
  3. August 6, 2026
    Employee stock plan registration S-8
  4. August 6, 2026
    Quarterly report 10-Q · period to June 27, 2026
  5. August 6, 2026
    Quarterly results 8-K
  6. July 28, 2026
    Executive or director change 8-K
  7. June 9, 2026
    Annual report to shareholders ARS
  8. June 9, 2026
    Additional proxy material DEFA14A
  9. June 9, 2026
    Proxy statement DEF 14A
  10. June 5, 2026
    Investor disclosure 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on July 28, 2026. Insider transactions on SEC

All filings on SEC EDGAR

Questions about HAE

What does Haemonetics Corp do?

Haemonetics Corp is registered with the SEC under industry code SIC 3841 (Surgical & Medical Instruments & Apparatus). Its shares trade on NYSE under the ticker HAE.

Is Haemonetics Corp profitable?

Yes. Over the twelve months to June 27, 2026 it reported net income of $96.3M on revenue of $1.4B, a net margin of 7.1%.

How much revenue does Haemonetics Corp make?

Over the twelve months to June 27, 2026 Haemonetics Corp reported revenue of $1.4B. That is 0.4% more than a year earlier.

When did Haemonetics Corp last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 27, 2026. Its newest filing of any kind is the investor disclosure from August 18, 2026.

Similar companies

MDLN
Medline Inc.
SYK
Stryker Corp
MMM
3M Co
BDX
Becton Dickinson & Co
BSX
Boston Scientific Corp
BAX
Baxter International Inc

Follow HAE

Get an email when Haemonetics Corp files with the SEC: results, executive changes, material agreements and annual reports.

Follow HAE: get an email when it files

Where the numbers come from

Financial figures are the values Haemonetics Corp tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.